Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2007

View Archived Issues

Genzyme reports on active first quarter

Novel therapeutic agents for neurological disorders reported in recent patent literature

Novel compounds claimed for use in respiratory disease treatment

CNS-5161, an NMDA receptor antagonist, profiled in vitro and in vivo

Lovastatin to enter the clinic for the treatment of recurrent melanoma / News in Context

Y's Therapeutics advances YSPSL to phase II trials for I/R injury

FDA committee endorses FluMist for children under 5

Vernalis and Servier Research join forces for drug discovery

Oxygent enters phase II for patients undergoing CABG surgery

Genzyme reports encouraging results in Gaucher disease study

Patient enrollment begins in phase III AWARE trial with Generx

Obecure evaluates OBE-101's ability to reduce caloric intake in phase II

BMS's once-daily HIV medicine option approved in Canada

FDA provides feedback for design of Cell Therapeutics' pixantrone phase III trial

MLN-0002 clinical program back on track

Orphan drug designation assigned to Levulan in U.S.

MethylGene selects candidate from antifungal program for clinic

Celladon and Targeted Genetics advance Mydicar into the clinic

Patient enrollment complete for Tovaxin MS trial

MitoPharm's Schisandrin B may hold potential for antiaging concerns

ProtoKinetix's AAGP shows promise in preclinical studies for diabetes

Biolitec's Foscan combined with PDT in SpectraCure prostate cancer clinical trial

Peregrine to study bavituximab for HCV/HIV co-infection

DelSite obtains license to NIH technology for typhoid vaccine

Diractin filed for European approval

Seroquel XR receives FDA approval

Lovenox approved for patients with STEMI

Novel VEGF inhibitor shows therapeutic potential in psoriasis mouse model

Approvable letter for Mircera

Ceftobiprole filed for U.S. approval for cSSSI

SPD-465 receives approvable letter for ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...